Printer Friendly

Cipla gets FDA nod for Sevelamer Carbonate tablets.

M2 PHARMA-October 27, 2017-Cipla gets FDA nod for Sevelamer Carbonate tablets

(C)2017 M2 COMMUNICATIONS

Indian multinational pharmaceutical and biotech company Cipla (NSE: CIPLA) confirmed on Friday that its subsidiary InvaGen Pharmaceuticals Inc has received final approval from the US Food and Drug Administration (FDA) for Sevelamer Carbonate tablets, 800 mg.

The company, which is headquartered in Mumbai, said that the drug is indicated for the treatment of serum phosphorus in adults with chronic kidney disease (CKD) on dialysis.

The product is the generic version of the reference listed drug, Genzyme Corporation's Renvela tablets, 800 mg.

Renvela tablets had US sales of approximately USD1.85bn for the 12 months ending August 2017, according to IMS Health.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 27, 2017
Words:127
Previous Article:FDA reviews Roche's Avastin as first-line treatment for ovarian cancer.
Next Article:Roche to present data for Ocrevus (ocrelizumab).
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters